Download
s15010-020-01549-7.pdf 601,22KB
WeightNameValue
1000 Titel
  • Impact of safety warnings for fluoroquinolones on prescribing behaviour. Results of a cohort study with outpatient routine data
1000 Autor/in
  1. Georgi, Ulrike |
  2. Tesch, Falko |
  3. Schmitt, Jochen |
  4. de With, Katja |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-11-30
1000 Erschienen in
1000 Quellenangabe
  • 49(3):447-455
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s15010-020-01549-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159769/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!The need for drug-related safety warnings is undisputed, but their impact on prescribing behaviour is not always clear. Safety warnings usually do not contain therapeutic alternatives. Based on German outpatient routine healthcare data, our cohort study investigated the impact of three warnings for fluoroquinolones on prescribing behaviour.!##!Methods!#!Structural breaks were estimated in a time-series analysis (2005-2014) of 184,134 first antibiotic prescriptions for patients (≥ 18 years) diagnosed with community-acquired pneumonia (CAP), acute bacterial sinusitis (ABS), or acute exacerbation of chronic bronchitis (AECB). Subsequently, risk factors for patients' before/after safety warnings presented as risk ratios (RR) were estimated by Poisson regression.!##!Results!#!Following the 2008 warning for moxifloxacin, the RR of being prescribed moxifloxacin was reduced by 56% (95% CI 0.41-0.47; p < 0.001) for CAP, by 65% (95% CI 0.32-0.39; p < 0.001) for ABS, by 57% (95% CI 0.41-0.45; p < 0.001) for AECB. After the 2012 warning for levofloxacin, the RR of being prescribed levofloxacin was reduced by 31% (95% CI 0.64-0.74; p < 0.001) for CAP, by 14% (95% CI 0.77-0.96; p = 0.007) for ABS, by 27% (95% CI 0.69-0.77; p < 0.001) for AECB. We noticed a prescription-switch to other antibiotics which was not in line with the national guideline recommendations. The warning for moxifloxacin 2009 had no impact on prescribing behaviour.!##!Conclusion!#!This study observed an impact on prescribing behaviour in response to regulatory safety warnings for two out of three warnings. Information on therapeutic alternatives should be a part of any safety warning to encourage the intended changes in prescribing behaviour.
1000 Sacherschließung
lokal Levofloxacin [MeSH]
lokal Pharmacovigilance
lokal Humans [MeSH]
lokal Patient safety
lokal Moxifloxacin [MeSH]
lokal Cohort Studies [MeSH]
lokal Anti-Bacterial Agents/adverse effects [MeSH]
lokal Antibiotic use
lokal Outpatients [MeSH]
lokal Fluoroquinolones/adverse effects [MeSH]
lokal Original Paper
lokal Cohort studies
lokal Fluoroquinolones
lokal Practice patterns
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-9896-3969|https://orcid.org/0000-0001-8933-643X|https://orcid.org/0000-0003-0264-0960|https://frl.publisso.de/adhoc/uri/ZGUgV2l0aCwgS2F0amE=
1000 Hinweis
  • DeepGreen-ID: 559b0e4cf0e641cc9e02720a55daa499 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6471770.rdf
1000 Erstellt am 2023-11-18T15:39:38.371+0100
1000 Erstellt von 322
1000 beschreibt frl:6471770
1000 Zuletzt bearbeitet 2024-04-05T12:08:40.671+0200
1000 Objekt bearb. Fri Apr 05 12:08:40 CEST 2024
1000 Vgl. frl:6471770
1000 Oai Id
  1. oai:frl.publisso.de:frl:6471770 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source